• Treatment of onchocerciasis (River Blindness).

Contraindicated in:

• None.

Use Cautiously in:

• Severe renal impairment or end-stage renal disease
• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Children <12 yr (safety and effectiveness not established)
• Geri: Older adults may have ↑ sensitivity to adverse reactions.

CV: hypotension, orthostatic hypotension, tachycardia, edema.

Derm: pruritus, rash, urticaria.

EENT: ↑ lacrimation, blurred vision, conjunctivitis, eyelid swelling, hyperemia, ocular itching, ocular pain, photophobia, watery eyes.

F and E: hyponatremia.

GI: abdominal pain, diarrhea, ↑ liver enzymes, hyperbilirubinemia.

Hemat: eosinophilia, leukocytosis, lymphocytopenia, neutropenia, eosinopenia.

MS: myalgia, arthralgia.

Neuro: headache, dizziness, ENCEPHALOPATHY (IF CO-INFECTED WITH LOA LOA), paresthesia.

Resp: cough.

Misc: chills, fever, lymphadenopathy.

Drug-Drug:

• None reported.

(Generic available)

• Tablets: 2 mg;

• PO (Adults and Children ≥12 yr): 8 mg as single dose.

• Causes increased permeability, influx of chloride ions, hyperpolarization, and muscle paralysis; affects the microfilariae, but does not kill the adult worm.

• Reduction in skin microfilarial density.

Spectrum:

• Onchocerca volvulus.

Therapeutic Classification:

Absorption: Absorption ↑ with a high-fat meal.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Undergoes minimal hepatic metabolism; 2% excreted in feces as unchanged drug.

Half-life: 23 days.

(plasma concentrations)

• Instruct patient to take moxidectin as directed.
• Advise patients that if they feel dizzy or lightheaded after taking moxidectin tablets, they should lie down until the symptoms resolve.
• Advise patient that flu like symptoms (malaise, myalgia, headache, tachycardia, hypotension, pruritus) may occur during 1st wk after treatment.
• Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
• Inform patient that moxidectin does not kill adult O. volvulus and follow up evaluation is usually required.

mox-i-DEK-tin

NDC Code^*

• 71705- Medicines Development Limited (trading as Medicines Development for Global Health)
  • 71705-050- Moxidectin
    • 71705-050-01- 1000 mg in 1 BOTTLE, PLASTIC (71705-050-01)